Tocagen — Forte Biosciences — Technical Presentation (July 2026)
21 slides from Tocagen's technical presentation, Jul 9, 2026
Slide 1: Forte FB102 Phase 1b Vitiligo Data
Forte FB102 Phase 1b Vitiligo Data July 9, 2026 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 2IE of the Securities and Exchange Act of 1934, as amended, and the Private Securities
Slide 3: Large unmet need in vitiligo presents a substantial market opportunity
Large unmet need in vitiligo presents a SUBSTANTIAL MARKET opportunity Vitiligo is an autoimmune disease of the skin driven by pathogenic T cells that kill melanocytes and create white spots Vitiligo results in sensitive skin (increasing likelihood of sun burns), eye abnormalities, emotional challen
Slide 4: IL-15 activation of pathogenic CD8+ T cells in skin
IL-15 activation of pathogenic CD8+ T cells in skin Vitiligo patients have unpigmented skin due activated pathogenic T cells killing melanocytes FB102 blocks activation of pathogenic T cells, restoring melanocyte health and skin pigmentation Tokura Front Immunol. 2021 PMID 33633737
Slide 5: IL-2 Therapy drives vitiligo
IL-2 Therapy drives vitiligo Journal of Investigative Derm. (2006) Vol 126 Journal of Clinical Oncology V19(15) Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma(1) Peter D. Boasberg1, Dave S.B. Hoon2, Lawrence D. Piro1, Maureen A. Martin1, A
Slide 6: An anti-CD122 antibody is effective in a mouse vitiligo model with established disease
An anti-cd122 antibody is effective in a mouse vitiligo model with established disease Repigmentation study Richmond, 2012. Sci Transl Med. 2018 PMID 30021889 Melanin-reactive T cells eliminated pigment in tail Anti-CD122 treatment restored pigmentation Vehicle (control) treatment did not restore pi
Slide 7: Anti-CD122 in a Mouse Model of Vitiligo: Potential of durable response with infrequent dosing
Anti-CD122 in a Mouse Model of Vitiligo: Potential of durable response with Infrequent Dosing Regimen Note: anti-mouse CD122 (surrogate molecule) was used in these studies.
Slide 8: FB102 Placebo Controlled Phase 1b Vitiligo
FB102 Placebo Controlled Phase IB ViTIligo
Slide 9: FB102-401 Double-Blind Placebo-Controlled Phase 1b Vitiligo Study Design
FB102-401 DOUBLE-BLIND PLACEBO-CONTROLLED Phase 1b Vitiligo STUDY DESIGN Screening Includes Central Read FVASI Randomization 3:1 Ratio FB102:PBO Safety Follow-up Treatment Week 1 6 9 12 16 24 Follow-up Cohort B (17 subjects) Placebo (11 Subjects) R Cohort A (15 subjects) Central Read FVASI 12-week t
Slide 10: Summary of FB102 Phase 1b Vitiligo Study
Summary of FB102 Phase 1b Vitiligo STUDY The FB102 phase 1b double-blind placebo-controlled vitiligo study enrolled 43 subjects 3:1 randomized with 11 on placebo and 32 on FB102. The primary endpoint of the study was mean percent FVASI improvement from baseline at week 24 as assessed by central-revi
Slide 11: ITT: Statistically significant primary endpoint of FVASI week 24 percent improvement
ITT: STATISTICALLY SIGNIFICANT PRIMARY ENDPOINT OF Fvasi week 24 percent improvement from baseline: Intent to treat (ITT) population Week 24 Mean % Improvement FB102 PBO (ITT: N=11) PBO Adjusted p-value Cohort A (N=15) 28.8% -16.2% +45.0 pts 0.013 Cohort B (N=17) 30.4% -16.2% +46.6pts 0.009 FB102 (N
Slide 12: EE: Statistically significant primary endpoint of FVASI week 24 percent improvement
EE: STATISTICALLY SIGNIFICANT PRIMARY ENDPOiNT OF FVASI week 24 percent improvement from baseline: PROTOCOL-DEFI NED Efficacy evaluable (EE) population Week 24 Mean % Improvement FB102 PBO (EE: N=10) PBO Adjusted p-value Cohort A (N=15) 28.8% 7.9% +20.9 pts 0.040 Cohort B (N=17) 30.4% 7.9% +22.5pts
Slide 13: Statistical significance achieved by day 64 and continued through 24 weeks
STATISTICAL SIGNIFICANCE ACHIEVED BY DAY 64 and continued through 24 weeks with 12-Week TREATMENT FVASI mean % improvement FB102 (N=32) PBO (N=10) PBO-Adjusted p-value Week 6 5.6% 0.3% +5.3 pts 0.059 Week 9 (Day 64) 14.4% 1.9% +12.5 pts 0.023 Week 12 21.9% 5.4% +16.5 pts 0.028 Week 16 28.6% 8.2% +20
Slide 14: Subjects with greater baseline vitiligo involvement outperformed on FB102
SUBJECTs WITH GREATER BASELINE VITILIGO INVOLVEMENT OUTPERFORMED ON FB102 (baseline FVASI ≥0.75) FVASI mean % improvement FB102 (N=17) PBO (N=4) PBO-Adjusted p-value Week 6 7.2% 0.5% +6.7 pts 0.167 Week 9 (Day 64) 19.4% 1.2% +18.2 pts 0.058 Week 12 29.6% 1.7% +27.9 pts 0.033 Week 16 40.2% 1.5% +38.7
Slide 15: FVASI improvement at week 24 vs competitors
Fvasi improvement at week 24 vs competitors (Phase 2 data) 5 Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023
Slide 16: Week 24 FVASI50 and FVASI75 data
Week 24 Fvasi50 and fvasi75 data Population FVASI50 FB102 FVASI50 PBO FVASI75 FB102 FVASI75 PBO Protocol Defined Efficacy-evaluable 11/32 (34.4%) 1/10 (10.0%) 4/32 (12.5%) 1/10 (10.0%) Baseline FVASI ≥0.75 10/17 (58.8%) 0/4 (0.0%) 4/17 (23.5%) 0/4 (0.0%) FB102 achieved FVASI50 of 58.8% in FVASI ≥0.7
Slide 17: FVASI50 at week 24 vs competitors
Fvasi50 at week 24 vs competitors (Phase 2 Data) Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023
Slide 18: FVASI75 at week 24 vs competitors
Fvasi75 at week 24 vs competitors (Phase 2 data) Passeron T, et al. eClinicalMedicine. 2024 Pandya AG, et al. J Am Acad Dermatol. 2025 Ezzedine K, et al. J Am Acad Dermatol. 2023
Slide 19: FB102 re-pigmentation
FB102 re-pigmentation Baseline FVASI = 0.75 Week 12 FVASI = 0.20 73% improvement Week 24 FVASI = 0.10 87% improvement
Slide 20: FB102-401 continues to demonstrate strong safety profile
FB102-401 CONTINUES TO DEMONSTRATE STRONG Safety PROFILE Safety FB102 Placebo ≥1 TEAE 25/32 (78.1%) 9/11 (81.8%) Mild (Grade 1) 23/32 (71.9%) 9/11 (81.8%) Moderate (Grade 2) 18/32 (56.3%) 6/11 (54.5%) Severe (≥ Grade 3) 0 0 FB102 continues to demonstrate a strong safety profile and compared favorabl
Slide 21: Summary
SummaRY In double-blind placebo-controlled study, FB102 demonstrated robust activity, with statistically significant improvement in vitiligo from baseline to week 24, statistically significant responses occurring early (day 64), robust responder analysis, and continuing improvement through week 24 a
Forte Biosciences — Technical Presentation (July 2026) on 6ix